FTC, Catalent and Novo Holdings
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
Newser on MSN4d
Novo Nordisk's Insulin Change Attracts CriticsA s a teen, Lecritia Roberts injected herself with insulin using a glass vial and a syringe to manage her type 1 diabetes, ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
Novo Nordisk announced the European Medicines Agency's CHMP has adopted a positive opinion, recommending approval of Alhemo as the ...
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback